CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 190 enrolled
Drug / intervention
Preservative-Free Tafluprost or vehicle +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01254604
NCT01254604Phase 3Completed
CompareCT.gov

A Phase III, Randomized, Active Comparator-Controlled, Four-Week, Double-Masked Clinical Trial to Compare the Efficacy and Safety of Preservative-Free MK-2452 (0.0015%) and Preservative-Free Timolol Maleate (0.5%) in Patients With Open-Angle Glaucoma or Ocular Hypertension in India

Merck Sharp & Dohme LLC·interventional·Posted Dec 6, 2010·Updated Sep 20, 2018

In Brief

A Phase 3 clinical trial evaluating Preservative-Free Tafluprost or vehicle and Preservative-Free Timolol maleate for Glaucoma and Ocular Hypertension. Completed, enrolled 190 participants.

Detailed Summary

This study will test the hypothesis that preservative-free tafluprost (MK-2452) is non-inferior to preservative-free timolol maleate with respect to the diurnal intraocular pressure (IOP) change from baseline after 4 weeks of therapy in participants with open-angle glaucoma or ocular hypertension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Ocular Hypertension
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 6, 2010
Enrollment StartDec 1, 2011
Primary CompletionMay 9, 2013
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 15.6 years ago

Interventions

Preservative-Free Tafluprost or vehicledrug

Preservative-free tafluprost (0.0015%) ophthalmic solution; Preservative-free vehicle ophthalmic solution (contains no active drug)

Preservative-Free Timolol maleatedrug

Preservative-free timolol maleate (0.5%) ophthalmic solution